XML 105 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Agreements (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 25, 2017
USD ($)
treatment
Dec. 18, 2013
USD ($)
Dec. 31, 2013
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
treatment
shares
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2017
Variable Interest Entity                      
Revenues               $ 295,000 $ 653,000 $ 277,000  
Amount contributed   $ 1,500,000 $ 1,500,000                
Equity interest   50.00% 50.00%                
Percentage of ownership control with disputes resolved through arbitration   50.00% 50.00%                
Voting rights               50.00%      
Loss from equity method investment       $ (4,000) $ (454,000) $ (4,000) $ (875,000) $ (1,018,000) (1,542,000) (1,561,000)  
Investment in joint venture       142,000   142,000   146,000 65,000    
Additional contribution in joint venture               1,100,000 1,750,000 1,500,000  
OvaXon, LLC                      
Variable Interest Entity                      
Equity interest                     50.00%
Loss from equity method investment       $ 0 $ (500,000) $ 0 $ 900,000 (1,000,000) (1,500,000) $ (1,500,000)  
Investment in joint venture               $ 100,000 100,000    
OvaTure Collaboration                      
Variable Interest Entity                      
Period of commercial milestone payment after the first commercial sale of collaborative arrangement               3 months      
MGH and Harvard                      
Variable Interest Entity                      
License and patent-related fees               $ 400,000      
Contingent milestone payments               10,700,000      
IVF Japan                      
Variable Interest Entity                      
Initial term of agreement (in years) 1 year                    
Period of material breach (in years) 30 days                    
Fixed fee revenue per treatment cycle $ 1,000                    
Reimbursed amount of lab operations and personnel costs $ 200,000             55,000      
Number of excess treatment cycles | treatment 100                    
Fixed fee revenue per excess treatment cycle $ 2,000                    
Revenues               63,400      
Fees for treatment cycles $ 50,000             $ 8,400      
IVF Japan | Minimum                      
Variable Interest Entity                      
Number of excess treatment cycles | treatment               50      
Intrexon                      
Variable Interest Entity                      
Amount contributed   $ 1,500,000                  
Equity interest   50.00%                  
Percentage of ownership control with disputes resolved through arbitration   50.00%                  
Additional contribution in joint venture               $ 1,100,000 $ 1,800,000    
Intrexon | OvaTure Collaboration                      
Variable Interest Entity                      
Issuance of common stock shares upon execution of collaborative arrangements (in shares) | shares               273,224      
Vesting of Founders Stock               $ 2,500,000      
Technology access fee payable in cash upon specified passage of time               $ 2,500,000